CONCLUSION
The combined deployment of AAEs and S-ICD in selected patients at very
high-risk of infections is safe, feasible and may offer a true clinical
benefit in specific clinical settings. None of the twenty-five patients
implanted with a combination of AAE and S-ICD in this proof-of-concept
study developed major device-related infectious complications in the
first year of follow-up and only a single, conservatively manageable,
pocket infection was experienced during in the entire cohort.